These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 15496144)

  • 1. Acceptance and rejection: cost-effectiveness and the working nephrologist.
    McFarlane PA; Bayoumi AM
    Kidney Int; 2004 Nov; 66(5):1735-41. PubMed ID: 15496144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms.
    Hogendoorn W; Lavida A; Hunink MG; Moll FL; Geroulakos G; Muhs BE; Sumpio BE
    J Vasc Surg; 2015 Jun; 61(6):1432-40. PubMed ID: 25827968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental cost effectiveness evaluation in clinical research.
    Krummenauer F; Landwehr I
    Eur J Med Res; 2005 Jan; 10(1):18-22. PubMed ID: 15737949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of alternative treatments for depression in low-income women.
    Beil H; Beeber LS; Schwartz TA; Lewis G
    J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases.
    Lal LS; Byfield SD; Chang EL; Franzini L; Miller LA; Arbuckle R; Reasonda L; Feng C; Adamus A; Swint JM
    Am J Clin Oncol; 2012 Feb; 35(1):45-50. PubMed ID: 21293245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.
    Hoerger TJ; Wittenborn JS; Segel JE; Burrows NR; Imai K; Eggers P; Pavkov ME; Jordan R; Hailpern SM; Schoolwerth AC; Williams DE;
    Am J Kidney Dis; 2010 Mar; 55(3):463-73. PubMed ID: 20116910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
    de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
    Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
    Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
    Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic approach to health care.
    Homik JE; Suarez-Almazor M
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial.
    Henderson C; Knapp M; Fernández JL; Beecham J; Hirani SP; Cartwright M; Rixon L; Beynon M; Rogers A; Bower P; Doll H; Fitzpatrick R; Steventon A; Bardsley M; Hendy J; Newman SP;
    BMJ; 2013 Mar; 346():f1035. PubMed ID: 23520339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis comparing 3 anterior cruciate ligament graft types: bone-patellar tendon-bone autograft, hamstring autograft, and allograft.
    Genuario JW; Faucett SC; Boublik M; Schlegel TF
    Am J Sports Med; 2012 Feb; 40(2):307-14. PubMed ID: 22085728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
    Teerawattananon Y; Mugford M; Tangcharoensathien V
    Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness acceptability curves and a reluctance to lose.
    Severens JL; Brunenberg DE; Fenwick EA; O'Brien B; Joore MA
    Pharmacoeconomics; 2005; 23(12):1207-14. PubMed ID: 16336015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant.
    Dowie J
    Health Econ; 2004 May; 13(5):453-9. PubMed ID: 15127425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinician's guide to correct cost-effectiveness analysis: think incremental not average.
    Hoch JS; Dewa CS
    Can J Psychiatry; 2008 Apr; 53(4):267-74. PubMed ID: 18478830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.
    Sendi P
    Pharmacoeconomics; 2021 Feb; 39(2):161-169. PubMed ID: 33128734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Power and sample size in cost-effectiveness analysis.
    Laska EM; Meisner M; Siegel C
    Med Decis Making; 1999; 19(3):339-43. PubMed ID: 10424840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.